These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26775042)

  • 1. Microbiome and bacterial translocation in cirrhosis.
    Gómez-Hurtado I; Such J; Francés R
    Gastroenterol Hepatol; 2016 Dec; 39(10):687-696. PubMed ID: 26775042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiota-related complications in cirrhosis.
    Gómez-Hurtado I; Such J; Sanz Y; Francés R
    World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the Microbiome in Cirrhosis and Relationship to Complications: Hepatic Encephalopathy, Spontaneous Bacterial Peritonitis, and Sepsis.
    Lachar J; Bajaj JS
    Semin Liver Dis; 2016 Sep; 36(4):327-330. PubMed ID: 27997972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infections in patients affected by liver cirrhosis: an update.
    Ascione T; Di Flumeri G; Boccia G; De Caro F
    Infez Med; 2017 Jun; 25(2):91-97. PubMed ID: 28603226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microflora in the pathogenesis of the complications of cirrhosis.
    Garcia-Tsao G; Wiest R
    Best Pract Res Clin Gastroenterol; 2004 Apr; 18(2):353-72. PubMed ID: 15123075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis.
    Runyon BA; Squier S; Borzio M
    J Hepatol; 1994 Nov; 21(5):792-6. PubMed ID: 7890896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of microbiome in patients with decompensated cirrhosis.
    Oikonomou T; Papatheodoridis GV; Samarkos M; Goulis I; Cholongitas E
    World J Gastroenterol; 2018 Sep; 24(34):3813-3820. PubMed ID: 30228776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence.
    Llovet JM; Bartolí R; March F; Planas R; Viñado B; Cabré E; Arnal J; Coll P; Ausina V; Gassull MA
    J Hepatol; 1998 Feb; 28(2):307-13. PubMed ID: 9580278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
    Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
    World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of spontaneous bacterial peritonitis in an experimental model in cirrhotic rats. Relationship with intestinal bacterial translocation].
    Martín L; Sánchez E; Casafont F; Agüero J; Ledesma P; Nevado N; Pons Romero F
    Rev Esp Enferm Dig; 1995 Sep; 87(9):632-6. PubMed ID: 7577121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis.
    Qamar AA
    J Clin Gastroenterol; 2015; 49 Suppl 1():S28-32. PubMed ID: 26447961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
    Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
    J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.
    Ponziani FR; Zocco MA; Cerrito L; Gasbarrini A; Pompili M
    Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):641-656. PubMed ID: 29806487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
    Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
    World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.
    Giannelli V; Di Gregorio V; Iebba V; Giusto M; Schippa S; Merli M; Thalheimer U
    World J Gastroenterol; 2014 Dec; 20(45):16795-810. PubMed ID: 25492994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers.
    Madsen BS; Havelund T; Krag A
    Adv Ther; 2013 Jul; 30(7):659-70. PubMed ID: 23881723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.